Immunome Business Summary

Immunome Inc. (IMNM) is a clinical-stage biopharmaceutical company that generates revenue through strategic licensing agreements, research and development collaborations, and milestone-based partnerships, while transitioning toward a commercial-stage oncology model. The company’s business is primarily segmented into its therapeutic pipeline—which focuses on first-in-class antibody-drug conjugates (ADCs), radioligand therapies, and small molecules—and its proprietary discovery platforms, including the RealMab™ memory B cell technology and the Targeted Effector platform. Its lead clinical asset, varegacestat (AL102), recently achieved its primary endpoint in a Phase 3 trial for desmoid tumors, positioning the company as a late-stage contender in the precision oncology market. Immunome operates within a competitive landscape alongside firms such as AbCellera, Atreca, and Jazz Pharmaceuticals, distinguishing itself through its unique ability to leverage the human immune response for antibody discovery and its aggressive acquisition of de-risked, late-stage oncology assets. The company is led by President and CEO Dr. Clay Siegall, the co-founder and former CEO of Seagen, who is a pioneer in the ADC field and oversaw Seagen’s $43 billion acquisition by Pfizer. The executive leadership team includes Chief Scientific Officer Dr. Jack Higgins, Chief Business Officer Kinney Horn, Chief Financial Officer Max Rosett, and Chief Technical Officer Phil Tsai, many of whom possess deep pedigrees from industry leaders like Seagen and Olema Oncology. Immunome was founded by Dr. Scott Dessain, whose foundational work in B cell hybridoma technology remains a cornerstone of the company’s platform. The firm is backed by a robust roster of institutional investors, including Enavate Sciences, EcoR1 Capital, and Redmile Group, with a board of directors featuring notable industry veterans such as Jean-Jacques Bienaimé, the former CEO of BioMarin Pharmaceutical, and Isaac Barchas of Research Bridge Partners.